{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-118569","form_type":"8-K","ticker":"LXEO","cik":"0001907108","company_name":"Lexeo Therapeutics, Inc.","filed_at":"2024-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.323957+00:00","generated_at":"2026-05-30T08:35:20.523612+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lexeo announces positive interim Phase 1/2 data for LX1001 gene therapy in APOE4 Alzheimer's","bullets":["LX1001 showed dose-dependent APOE2 expression in all participants with durability to 12 months.","CSF tau biomarkers (T-tau, P-tau181, P-tau217, P-tau231) reduced in >2/3 of participants relative to baseline.","No reports of ARIA; four SAEs reported, one hearing loss possibly related, repeat audiometry pending.","Company initiated FDA engagement; expects update on regulatory interactions and development plans in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-118569","json":"https://secwatch.observer/filing/0000950170-24-118569.json","markdown":"https://secwatch.observer/filing/0000950170-24-118569.md","text":"https://secwatch.observer/filing/0000950170-24-118569.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1907108/000095017024118569/0000950170-24-118569-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1907108/000095017024118569/lxeo-20241030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T08:35:20.523612+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}